Dongwha Pharm.Co.Ltd Beheer

Beheer criteriumcontroles 0/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Doh Yoon

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	9.0%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Mar 26

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Apr 28

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Mar 11

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Dec 19

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Dec 04

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Nov 19

CEO

Doh Yoon (72 yo)

no data

Tenure

Mr. Doh Joon Yoon serves as the Chairman of the Board and Co-Chief Executive Officer of Dongwha Pharm Co.,Ltd. Mr. Yoon serves as an Advisor of the Korean College of Neuropsychopharmacology (KCNP). He serv...

Dongwha Pharm.Co.Ltd Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Dongwha Pharm.Co.,Ltd, Annual General Meeting, Mar 25, 2021

Recent updates

New major risk - Financial data availability

New minor risk - Profit margin trend

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Full year 2023 earnings released: EPS: ₩991 (vs ₩736 in FY 2022)

Upcoming dividend of ₩180 per share at 1.8% yield

Full year 2022 earnings released: EPS: ₩736 (vs ₩647 in FY 2021)

Upcoming dividend of ₩180 per share

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₩180 per share

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS ₩197 (vs ₩82.00 in 1Q 2020)

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Full year 2020 earnings released: EPS ₩1,033 (vs ₩330 in FY 2019)

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Dongwha Pharm.Co.,Ltd, Annual General Meeting, Mar 25, 2021

New 90-day low: ₩14,500

Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

New 90-day low: ₩17,050

Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Investor sentiment deteriorated over the past week

Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

Upcoming Dividend of ₩120 Per Share

Investor sentiment improved over the past week

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Market bids up stock over the past week

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Market pulls back on stock over the past week

Market pulls back on stock over the past week

New 90-day low: ₩20,300

Dongwha Pharm.Co.,Ltd (KOSE:A000020) agreed to acquire additional 11.18% stake in MEDYSSEY Co.,Ltd (XKON:A200580) for KRW 4 billion.

Dongwha Pharm.Co.,Ltd (KOSE:A000020) completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd (XKON:A200580) from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim.

Dongwha Pharm.Co.,Ltd (KOSE:A000020) agreed to acquire 53.3% stake in MEDYSSEY Co.,Ltd (XKON:A200580) from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim for KRW 19.6 billion.

New 90-day high - ₩21,650

CEO

Tenure